L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent et al., Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012.

J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., and SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-90, 2008.

M. S. Matter, T. Decaens, J. B. Andersen, and S. S. Thorgeirsson, Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends, J Hepatol, vol.60, pp.855-65, 2014.

I. Kunter, E. Erdal, D. Nart, F. Yilmaz, S. Karademir et al., Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma, Oncol Rep, vol.31, pp.573-80, 2014.

K. F. Chen, H. L. Chen, W. T. Tai, W. C. Feng, C. H. Hsu et al., Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells, J Pharmacol Exp Ther, vol.337, pp.155-61, 2011.

B. Zhai, F. Hu, H. Yan, D. Zhao, J. X. Fang et al., Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress, PLoS One, vol.10, p.138485, 2015.

M. Hanada, J. Feng, and B. A. Hemmings, Structure, regulation and function of PKB/AKT-a major therapeutic target, Biochim Biophys Acta, vol.1697, pp.3-16, 2004.

D. Koeberle, J. F. Dufour, G. Demeter, Q. Li, K. Ribi et al., Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29), Ann Oncol, vol.27, pp.856-61, 2016.

A. X. Zhu, M. Kudo, E. Assenat, S. Cattan, Y. K. Kang et al., Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, vol.312, pp.57-67, 2014.

M. Breuleux, M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys et al., Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition, Mol Cancer Ther, vol.8, pp.742-53, 2009.

G. S. Roth, M. Jilkova, Z. , Z. Kuyucu, A. Kurma et al., Efficacy of AKT inhibitor ARQ 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma, Mol Cancer Ther, vol.16, pp.2157-65, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02333028

J. Rodon, R. Dienstmann, V. Serra, and J. Tabernero, Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, vol.10, pp.143-53, 2013.

B. Zhai, F. Hu, X. Jiang, J. Xu, D. Zhao et al., Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma, Mol Cancer Ther, vol.13, pp.1589-98, 2014.

E. Schiffer, C. Housset, W. Cacheux, D. Wendum, C. Desbois-mouthon et al., Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis, Hepatology, vol.41, pp.307-321, 2005.

T. K. Lee, V. C. Cheung, P. Lu, E. Y. Lau, S. Ma et al., Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma, Hepatology, vol.60, pp.179-91, 2014.

J. Lo, E. Y. Lau, R. H. Ching, B. Y. Cheng, M. K. Ma et al., Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice, Hepatology, vol.62, pp.534-579, 2015.

K. Schulze, S. Imbeaud, E. Letouze, L. B. Alexandrov, J. Calderaro et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-516, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01159736

J. Friemel, M. Rechsteiner, L. Frick, F. Bohm, K. Struckmann et al., Intratumor heterogeneity in hepatocellular carcinoma, Clin Cancer Res, vol.21, pp.1951-61, 2015.

X. X. Ding, Q. G. Zhu, S. M. Zhang, L. Guan, T. Li et al., Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy, Oncotarget, vol.8, pp.55715-55745, 2017.

D. Thabut and V. Shah, Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?, J Hepatol, vol.53, pp.976-80, 2010.

D. Thabut, C. Routray, G. Lomberk, U. Shergill, K. Glaser et al., Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis, Hepatology, vol.54, pp.573-85, 2011.

K. Qu, Z. Huang, T. Lin, S. Liu, H. Chang et al., New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials, Front Pharmacol, vol.6, p.300, 2016.

W. K. Xiao, D. Chen, S. Q. Li, S. J. Fu, B. G. Peng et al., Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis, BMC Cancer, vol.14, p.117, 2014.

T. C. Xue, L. Zhang, X. Y. Xie, N. L. Ge, L. X. Li et al., Prognostic significance of the neutrophil-tolymphocyte ratio in primary liver cancer: a meta-analysis

, PLoS One, vol.9, 2014.

K. Kim, J. Li, A. Barazia, A. Tseng, S. W. Youn et al., ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease, Haematologica, vol.102, pp.246-59, 2017.

S. L. Zhou, Z. J. Zhou, Z. Q. Hu, X. W. Huang, Z. Wang et al., Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib, Gastroenterology, vol.150, pp.1646-1658, 2016.

C. L. Wilson, D. Jurk, N. Fullard, P. Banks, A. Page et al., NFkappaB1 is a suppressor of neutrophil-driven hepatocellular carcinoma, Nat Commun, vol.6, p.6818, 2015.

M. Jilkova, Z. Afzal, S. Marche, H. Decaens, T. Sturm et al., Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils, Liver Int, vol.36, pp.1116-1140, 2016.

M. Jilkova, Z. Decaens, T. Marlu, A. Marche, H. Jouvin-marche et al., Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels, Mediators Inflamm, p.3214917, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02333383